Our lead break-through prebiotic personal lubricant "PreBioGyn" is being developed to optimize vaginal health to reduce disruptions of the vaginal ecosystem that increase cervical cancer and vaginal infection risks, especially for people in low resource settings (LRS) with poor healthcare access. These people are those most at risk of developing cervical cancer, the 4th most frequent female cancer worldwide, and a U.S. demographic currently experiencing a “staggering rise” in death rates from this cancer.
Our NCI Phase I STTR “Cervical Cancer Prevention Prebiotic Device” was completed in late 2023, and funded under NOT-CA-21-062 (Cancer Prevention, Diagnosis, and Treatment Technologies for Low- Resource Settings). Glyciome has also received funding from the Health Sciences and Services Authority (HSSA) of Spokane County for development of this first-in-class prebiotic lubricant, which received its first issued US patent in 2024, with continued patent issuance and filing in 2025.
Our Related Technology Pipeline
Our direct-to-consumer (DTC) Wild & Pure® prebiotic, total-body cleansers (wildandpure.com) are used for skin and genital care across all ages. Wild & Pure* won the 2021 Idaho Innovation Award for Consumer Product of the Year. Our ‘Natural’ version is EWG-verified® which assure consumers of the rigorous scientific review these products have undergone to meet the highest standards in safety.
Our near-market, kraft-paper vaginal applicator was developed during Phase I for PreBioGyn gel delivery and decreases waste and plastic contaminant exposure during gel application.
Our translational-stage related mobile app will monitor vaginal health and increase product-fit awareness for patients and providers during use of PreBioGyn and other vaginal products.
Our early-stage, carbon nanotube biosensor is a rapid, user-directed diagnostic screen for bacterial vaginosis (BV), the most common of all vaginal infections.
Glyciome is uniquely positioned to revolutionize global health – including women’s health, and grow bioscience business jobs in Spokane through commercialization of our disruptive technologies. Completed PreBioGyn Phase I STTR studies provided significant de-risking and feasibility support for commercialization of our cervical cancer prevention gel.
